Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00051324 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Neurobiological Predictors of Huntington's Disease (PREDICT-HD)

Study acronym: PREDICT-HD
StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated January 14, 2025 (before its estimated June 30, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Lead sponsor: University of Iowa to Jordan Schultz Primary and study completion dates: Jun 30, 2024 to Jun 30, 2025v27 Show 1 more changeShow less
    • Primary and study completion dates: Jun 30, 2024 to Jun 30, 2025
  2. Primary and study completion dates: Mar 31, 2023 to Jun 30, 2024 Trial status: Recruiting to Active, Not Recruiting · Site details revisedv26 Show 2 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
  3. Lead sponsor: Jane S. Paulsen to University of Iowav25
  4. Lead sponsor: University of Iowa to Jane S. Paulsen Trial status: Active, Not Recruiting to Recruiting · Primary completion date: Aug 31, 2017 to Mar 31, 2023 · Enrollment target: 1500 to 1700 · 2 morev24 Show 5 more changesShow less
    • Trial status: Active, Not Recruiting to Recruiting
    • Primary completion date: Aug 31, 2017 to Mar 31, 2023
    • Enrollment target: 1500 to 1700
    • Study sites: 0 to 1
    • Completion date: Dec 2018 to Mar 31, 2023
  5. Primary endpoints revised (3) Study sites: 27 to 0 · Primary completion date changed from estimate of Aug 2017 to Aug 31, 2017 · Completion date: Aug 2017 to Dec 2018v23 Show 3 more changesShow less
    • Study sites: 27 to 0
    • Primary completion date changed from estimate of Aug 2017 to Aug 31, 2017
    • Completion date: Aug 2017 to Dec 2018

    See this version in full on ClinicalTrials.gov ↗

Show 21 earlier versionsHide 21 earlier versions
  1. Primary and study completion dates: Aug 2016 to Aug 2017v22
  2. Trial status: Recruiting to Active, Not Recruiting Site details revised at 27 of 27 sitesv21 Show 1 more changeShow less
    • Site details revised at 27 of 27 sites
  3. Primary and study completion dates: Aug 2015 to Aug 2016 Site contacts updated at 1 of 27 sitesv20 Show 1 more changeShow less
    • Site contacts updated at 1 of 27 sites
  4. Primary and study completion dates: Aug 2014 to Aug 2015 Eligibility criteria expanded, about 22 words · Study description expanded, about 8 words · Site details revised at 27 of 27 sitesv19 Show 3 more changesShow less
    • Eligibility criteria expanded, about 22 words
    • Study description expanded, about 8 words
    • Site details revised at 27 of 27 sites

    See this version in full on ClinicalTrials.gov ↗

  5. Primary and study completion dates: Aug 2013 to Aug 2014v18
  6. Enrollment target: 1100 to 1500 Study sites: 32 to 27 · Eligibility criteria revised · Study description shortened, about 1 wordv17 Show 3 more changesShow less
    • Study sites: 32 to 27
    • Eligibility criteria revised
    • Study description shortened, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  7. Re-verified, no change to tracked fieldsv16
  8. Site contacts updated at 5 of 32 sitesv15
  9. Re-verified, no change to tracked fieldsv14
  10. Site details revised at 1 of 32 sitesv13
  11. Enrollment target: 990 to 1100 Primary completion date: Aug 2013 · Completion date: Aug 2008 to Aug 2013 · Site contacts updated at 7 of 32 sitesv12 Show 3 more changesShow less
    • Primary completion date: Aug 2013
    • Completion date: Aug 2008 to Aug 2013
    • Site contacts updated at 7 of 32 sites
  12. Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS) to University of Iowa Collaborators expanded, about 8 wordsv11 Show 1 more changeShow less
    • Collaborators expanded, about 8 words

    See this version in full on ClinicalTrials.gov ↗

  13. Completion date: Aug 2008 Site contacts updated at 1 of 32 sitesv10 Show 1 more changeShow less
    • Site contacts updated at 1 of 32 sites
  14. Site contacts updated at 4 of 32 sitesv9
  15. Enrollment target: 925 to 990 Site contacts updated at 2 of 32 sitesv8 Show 1 more changeShow less
    • Site contacts updated at 2 of 32 sites
  16. Enrollment target: 900 to 925v7
  17. Enrollment target: 650 to 900 Study sites: 25 to 32v6 Show 1 more changeShow less
    • Study sites: 25 to 32
  18. 3 versions Re-verified since Nov 7, 2005, no change to tracked fieldsv3-v5
  19. Site contacts updated at 3 of 25 sitesv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this trial is to study early brain and behavioral changes in people who have the gene expansion for Huntington's disease, but are currently healthy and have no symptoms.
Trial Details
NCT Number NCT00051324
Lead Sponsor Jordan Schultz
Collaborators: National Institute of Neurological Disorders and Stroke (NINDS)
Conditions Huntington Disease
Enrollment 1,700 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov